Gubra A S (GUBRF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the conference call. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now I will hand the conference over to the speakers. Please go ahead. Good morning, everybody. Welcome to our Q1 investor call. I will go through a couple of highlights of the first quarter and then hand over to the team to continue. A quick reminder, GUPA operates via a business model involving three distinct but synergistic business units. We have our biotech unit where we discover and develop peptide therapeutics and we have a validated platform with multiple obesity assets in clinical development. We have our COO, where we provide preclinical research services to external and internal customers. And we have also now established Cupra Ventures, where we invest in high-quality science adjacent to our core areas. Given I've recently received questions, I also want to be clear that Cupra Ventures is not a corporate venture fund. Coming out a record year, 2025, we have started 2026 with great momentum in our biotech pipeline. A few recent events. In the beginning of the year, we have started to expand our facilities here in Herson at the DTU Science Park. So we are significantly expanding our lab facilities, which is beneficial to our internal discovery group, but as well as our COO, that we can do more studies in the future. We have strengthened our clinical leadership. with the recruitment of Thomas. Thomas is our chief development medical officer and given the focus on clinical development of multiple assets in parallel in the future, this is an important step for the company. We have also progress on partner progr...